Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

ators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST."

Following the recommendation of a data monitoring committee, the study will be closed and patients in the study who are currently being treated with placebo may choose to receive one year of Gleevec.

In the study, patients were randomized to one of two treatment arms. Neither the patients nor physicians knew which treatment the patients were receiving. One patient group received Gleevec at a dose of 400 milligrams per day for one year, while the second group received placebo for one year. According to the study design, patients who developed a recurrence of their cancer while on a study therapy were unblinded to their treatment assignment. Those receiving placebo subsequently received Gleevec, while those already given Gleevec continued with this therapy but at a higher dose. Study results will be presented at a forthcoming scientific meeting.

Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas that usually arise from the intestinal tract, with the most common site being the stomach followed by the small intestine. The incidence of GIST is estimated to be 4,500-6,000 new cases per year in the US (15-20 cases per million population), of which more than 90% are kit-positive.

Investigators in the NCI study reported that Gleevec therapy was well tolerated by most patients, with side effects similar to those observed in other clinical trials with Gleevec. These include nausea, diarrhea and swelling (edema). Information on more than 600 patients enrolled in the study was used in the analysis.

About Gleevec

Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. There are no controlled trials demon
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:3/3/2015)... -- This industry report package offers the most up-to-date market data on the ... world and in the top 10 global countries. Along with a global ... countries: Australia , China ... Italy , Japan , Russia ... , United States The reports include ...
(Date:3/3/2015)... , March 3, 2015 /CNW/ - The ... seized a health product being injected at Art Nails Ltd., located ... appeared to be unauthorized as it contained no labelling. All products ... authorized by Health Canada and must have approved labelling. ... had been administered to consumers. Potential risks associated with injecting an ...
(Date:3/3/2015)... , March 3, 2015 ... 356 and 240 patients respectively Publications in ... Journal of Clinical Gastroenterology highlight diagnostic value of ... China and across ... Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the ...
Breaking Medicine Technology:Global Safety Glass Market to 2019 - Market Size, Top 10 Countries, Trends, and Forecasts 2Advisory - Health product seized from Art Nails in Vancouver 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
(Date:3/3/2015)... DePuy Pinnacle hip lawsuits (( ... the artificial hip system caused recipients to suffer ... in the federal multidistrict litigation underway in U.S. ... the most recent Master Case List issued by ... hip replacement lawsuits are now pending in the ...
(Date:3/3/2015)... With a grant of more than $4.5 ... has been named a national coordinating center by the ... for Health: Improving Community Health Through Innovations in Financing ... health and reduce disparities through innovations in collaboration and ... of the center and up to 10 communities over ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Dallas ... as chairman of the upcoming Dallas Rhinoplasty Symposium, to ... three day symposium, which is attended by plastic surgeons ... provide surgeons with detailed information on current topics, emerging ... revision rhinoplasty surgery . , The symposium will ...
(Date:3/3/2015)... March 03, 2015 Retrofit , ... at America’s leading corporations, today announces the appointment of ... executive positions. CEO Mary Pigatti has recruited ... and employee engagement for the fast-growing company, which was ... watch for 2015. , “Retrofit is thrilled to ...
(Date:3/3/2015)... Celestix Networks, the leading provider ... the global availability of Celestix Cloud Edge Security ... most deployed platform for DirectAccess and remote access ... new release enables organizations to manage the Windows® ... single HTML 5 web interface called Comet 2.0. ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4Health News:Robert Wood Johnson Foundation Names Georgia Health Policy Center National Center for Bridging for Health Initiative 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 2Health News:Dr. Rod Rohrich to Chair 32nd Annual Dallas Rhinoplasty Symposium 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 2Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 3
... medicine is world renowned. It has supernatural effects on ... such article was recently reported in the November 7 ... the great significance of a Chinese medicinal compound, delisheng, ... method. The research team was led by Dr. Ke-Jun ...
... ID at-risk patients years before clinical diagnosis, scientists say ... An international team of scientists has developed a blood ... impairment will go on to develop Alzheimer,s disease. , ... of effective treatments against Alzheimer,s in the future -- ...
... October 15, 2007 New research presented at ... College of Gastroenterology emphasizes the importance of colorectal ... who have a higher incidence of colorectal cancer ... African-Americans had advanced polyps on the right side ...
... 2007 Post-hoc and other analyses of secondary endpoints ... plc,s (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis ... in patients with mild to moderate ulcerative colitis. These ... open-label 12-14 month extension study, are being presented this ...
... Level I and II,Trauma Center accreditation status has been ... 2007 through,September 30, 2008: Regional Resource Trauma Center (Level ... Johnstown -- Conemaugh Memorial Medical Center ... Philadelphia -- Hahnemann University Hospital ...
... TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals ... of cancer therapies, today announced that it held ... Drug Administration (FDA) at,which the FDA concurred with ... its lead drug, Neuradiab, a treatment for newly ...
Cached Medicine News:Health News:A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma 2Health News:Blood Test Might Spot Alzheimer's Early 2Health News:Blood Test Might Spot Alzheimer's Early 3Health News:Racial and ethnic differences in colorectal cancer emphasize importance of screening 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 4Health News:Pennsylvania Trauma Center Accreditation Status 2Health News:Bradmer provides Phase III Neuradiab trial update and guidance 2Health News:Bradmer provides Phase III Neuradiab trial update and guidance 3
The iQ200 Automated Urinalysis System (iQ System) is a user-friendly, bench top, fully automated system that performs complete urinalyses on unspun specimens; simply load, press START and walk away....
... the C6 peptide antigen, a 26 amino acid ... peptide has been shown to represent the immunodominant ... antigenic reactivity of the whole protein. Recent ... a sensitive and specific marker for antibody to ...
A flexible hematology platform:, 32 parameters, Automatic result validation, Cytology atlas included, CBC and 5+3 DIFF...
... 3W L.E.D. is mounted coaxially on the ... lithium battery pack giving 4 hours continuous ... packs and a charging unit that can ... well as being a convenient container to ...
Medicine Products: